Abstract
BackgroundTo evaluate the association between the therapeutic outcomes of sorafenib for advanced hepatocellular carcinoma (HCC) and the parameters of intravoxel incoherent motion (IVIM).MethodsNine patients were evaluated prospectively. All patients were Child-Pugh score A. The mean dimension of the lesion was 32 mm (range: 15–74 mm). MR images were obtained using a 1.5-Tesla superconductive MRI system. Diffusion-weighted imaging was performed under breath-holding using b-values of 0, 50, 100, 150, 200, 400, and 800 s/mm2. The following IVIM parameters were calculated: apparent diffusion coefficient, true diffusion coefficient (DC), pseudo-diffusion coefficient, and perfusion fraction. MRI was performed before treatment and at 1, 2, and 4 weeks after beginning treatment. Tumor response at 4 weeks was assessed by CT or MRI using modified RECIST. IVIM parameters of the treatment responders and non-responders were compared.ResultsThe DC of responders at baseline was significantly higher than that of the non-responders. The sensitivity and specificity, when a DC of 0.8 (10−3 mm2/s) or higher was considered to be a responder, were 100 % and 67 %, respectively. No significant differences were found in the other parameters between the responders and the non-responders. All IVIM parameters of the responders and non-responders did not change significantly after treatment.ConclusionThe DC before treatment may be a useful parameter for predicting the therapeutic outcome of sorafenib for advanced HCC.
Highlights
To evaluate the association between the therapeutic outcomes of sorafenib for advanced hepatocellular carcinoma (HCC) and the parameters of intravoxel incoherent motion (IVIM)
Other studies have concluded that diffusion-weighted imaging (DWI) was useful for the evaluation of the therapeutic outcomes of advanced HCC, and did not require data on arterial blood flow in Shirota et al Cancer Imaging (2016) 16:1 the lesion [6,7,8]
Six patients were classified as responders (Complete Response: 1; Stable Disease: 5), and 3 patients were classified as non-responders
Summary
To evaluate the association between the therapeutic outcomes of sorafenib for advanced hepatocellular carcinoma (HCC) and the parameters of intravoxel incoherent motion (IVIM). The multikinase inhibitor sorafenib was reported to prolong the median survival and time to progression of patients with advanced hepatocellular carcinoma (HCC) [1]. Sorafenib inhibits tumor-cell proliferation and tumor angiogenesis [2] This drug prolongs the stable state of HCC by reducing blood flow to the tumor and by increasing tumor-cell apoptosis, rather than by decreasing. Other studies have concluded that diffusion-weighted imaging (DWI) was useful for the evaluation of the therapeutic outcomes of advanced HCC, and did not require data on arterial blood flow in Shirota et al Cancer Imaging (2016) 16:1 the lesion [6,7,8]. The bleeding or necrosis of tumors increased diffusion values in the responder group [6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
